Acute Management of Cocaine-Associated Methaemoglobinaemia

Immo Weichert

Acute Medicine Unit, Royal Alexandra Hospital, Corsebar Road, Paisley PA2 9PN, UK

Correspondence should be addressed to Immo Weichert, immo.weichert.mail@gmail.com

Received 13 June 2011; Accepted 21 November 2011

1. Case Presentation

A 29-year-old man presented himself to the emergency department after noticing that his lips and fingers had turned blue. He had been on a cocaine binge preceding his admission. He estimated that he had been taking at least 14 grams over a period of five days. He felt short of breath on moderate exertion but denied chest pain or any other systemic symptoms. He had been using cocaine regularly for at least ten years, always via the nasal passageways, never injected, and denied taking any other recreational drugs. He was not on any prescription or over-the-counter medications. His only past medical history was of alcohol dependence, though he had not drunk in excess for at least ten months. There was no significant family history. He was alert and coherent, but slightly anxious. He was aphyrexic, his noninvasive blood pressure was 135/96 mmHg, and his heart rate was 85 beats/min. He was tachypnoeic with a respiratory rate of 18/min. There was marked cyanosis of his fingers and lips, and he was, immediately upon arrival in the emergency department, commenced on high flow oxygen. His saturation measured by pulse oximetry (SO2) was 86% on 15 L of oxygen given via a nonrebreathing mask. Arterial blood gasses showed H+ 50.9 nmol/L, pCO2 5.8 kPa, pO2 72.3 kPa, lactate 0.7 mmol/L, bicarbonate 26.0 mmol/L, CO HB 0.0%. His oxygen saturation on the blood gas (O2 Hb) was 66.6% and his methaemoglobin (Met Hb) level 32.9%. Chest X-Ray, ECG, full blood count, and routine biochemistry were unremarkable.

A diagnosis of methaemoglobinaemia was made, and he received one dose of methylene blue (1 mg/kg) intravenously over five minutes. He was transferred to the high dependency unit where he continued to receive high flow oxygen and was closely monitored.

His methaemoglobin levels, as well as his saturation, improved steadily over the next hours (Table 1). He made a full recovery and was discharged home the same evening after review by the local drug addiction liaison service with no further followup.

2. Discussion

Acquired methaemoglobinaemia is a well-recognized though still relatively rare complication of cocaine use. It is attributed to adulterants, cheaper substances that are being mixed with the pure cocaine base to increase the profits from selling the drug. Local anaesthetics are being used as they will produce a similar sensation when applied to mucosal surfaces as unadulterated cocaine [1]. Benzocaine is often implied in acquired methaemoglobinaemia, though its use as adulterant does vary between countries. Benzocaine is the most frequently found cutting agent in the UK [2] while a recent French study failed to show its significant use there [3].

Methaemoglobinaemia is caused by oxidation of the iron molecule in the heme group to the ferric state (Fe 3+). This renders it unable to carry oxygen and causes a functional anaemia. Blood normally can contain about 1% of methaemoglobin. Substances that put high oxidative stresses onto haemoglobin will increase the level above normal. Well-recognized causes for this are local anaesthetics (especially
Failure should be treated after obtaining advice from the agent and to distinguish primary from secondary causes of methaemoglobinemia. In cases where the cyanosis has not improved after increasing the oxygen supply, as well as in patients with comorbidities, this can occur at much lower levels.

Methaemoglobin interferes with traditional (not multi-wavelength) pulse oximetry. In patients with relatively low methaemoglobin levels this will give falsely low oxygen saturations. Paradoxically, it will also lead to falsely elevated oxygen saturations in the presence of significant concentrations. Arterial blood gasses will often show normal oxygen saturations in the presence of significant methaemoglobin levels. At relatively low levels this will lead to a cyanotic but asymptomatic patient. Typically, the cyanosis will not improve after increasing the oxygen supply. Symptoms in otherwise healthy individuals will start at methaemoglobin levels of 30% or more. These will be related to oxygen deficiency in organs with high demands, that is, the cardiovascular and central nervous system. Patients will experience headaches, lightheadedness, anxiety, dyspnoea, palpitations, and somnolence. Significant toxicity will occur at methaemoglobin levels of 50% and over. This will include cardiac arrhythmias, delirium, seizures, coma as well as a profound metabolic acidosis. Death will occur at concentrations above 60% [4], though in patients with comorbidities this can occur at much lower levels.

Methaemoglobinemia is the antidote of choice if methaemoglobin levels have been removed, Met Hb levels will return to normal within 36 hours [9]. Methylene blue (methylthioninium chloride) is the antidote of choice if methaemoglobin levels have reached 30% or if there is symptomatic hypoxaemia or ischaemia [10]. It leads to the reduction of methaemoglobin both via the NADPH-methaemoglobin reductase as well as through its own intermediary, leucomethylene blue [11]. The initial dose is 1 mg/kg bodyweight given intravenously over five minutes. Effects will be measurable within 30 minutes to one hour. In severe toxicity, this may have to be repeated. Failure to respond to methylene blue suggests G6PD deficiency where it can also cause profound haemolysis. Repeated or high doses can lead to a paradoxical increase in methaemoglobin [12]. Its effects during pregnancy are unsure, and potential risks of teratotoxicity need to be considered [13]. It can cause blue discolouration of the urine as well as of the sclera [14]. Other rare but serious side effects are related to its MAO-inhibitor action [15], and it has been implied in the serotonin syndrome [16]. The latter is a potentially life-threatening condition caused by excessive serotonergic activity in the nervous system. Features include mental status changes, autonomic instability, and neuromuscular hyperactivity [17]. Patients who have been on selective serotonin reuptake inhibitor antidepressants (SSRIs) or clomipramine and are treated with methylene blue should be observed for CNS effects for up to four hours after administration [18]. Alternative treatments which have been successfully used in significant methaemoglobinemia, or in patients that are unable to take methylene blue, are hyperbaric oxygen and exchange transfusions [19].

The prognosis of methaemoglobinemia is determined by the degree of end-organ damage. Mild-to-moderate severe cases will make a complete and swift recovery. Recurrent presentations, partial or nonresponse to methylene blue, should raise suspicion of a primary methaemoglobinemia or G6PD deficiency and warrant further specialist assessment.

### Conflict of Interests

No conflicts of interest have been declared.

### References

[1] C. D. McKinney, K. F. Postiglione, and D. A. Herold, “Benzocaine-adultered street cocaine in association with methemoglobinemia,” Clinical Chemistry, vol. 38, no. 4, pp. 596–597, 1992.

[2] UK Border Agency, “Further benzocaine seizure at Felixstowe,” 2010, http://www.ukba.homeoffice.gov.uk/sitecontent/newsarticles/2010/275292/25benzocain-felixstowe.

[3] I. Evrard, S. Legleye, and A. Cadet-Tairou, “Composition, purity and perceived quality of street cocaine in France,”
E. J. Benz, “Disorders of hemoglobin,” in Harrison’s Principles of Internal Medicine, A. S. Fauci, E. Braunwald, and D. L. Kasper, Eds., chapter 99, McGraw-Hill, New York, NY, USA, 17th edition, 2010.

S. J. Barker, K. K. Tremper, and J. Hyatt, “Effects of methemoglobinemia on pulse oximetry and mixed venous oximetry,” Anesthesiology, vol. 70, no. 1, pp. 112–117, 1989.

S. T. Nguyen, R. E. Cabrales, C. A. Bashour et al., “Benzocaine-induced methemoglobinemia,” Anesthesia and Analgesia, vol. 90, no. 2, pp. 369–371, 2000.

E. Oechslin, “Hemoglobin cyanosis,” in Siegenthaler’s Differential Diagnosis in Internal Medicine, W. Siegenthaler, Ed., chapter 21.2, p. 709, Thieme, Stuttgart, Germany, 1st edition, 2005.

I. Beckley, N. A. A. Ansari, H. A. Khwaja, and Y. Mohsen, “Clinical management of cocaine body packers: the Hillingdon experience,” Canadian Journal of Surgery, vol. 52, no. 5, pp. 417–421, 2009.

S. C. Curry, “Hematologic syndromes: hemolysis, methemoglobinemia, and sulfhemoglobinemia,” in Critical Care Toxicology, J. Brent, Ed., p. 339, Elsevier-Saunders, 2004.

T. S. Do Nascimento, R. O. L. Pereira, H. L. D. De Mello, and J. Costa, “Methemoglobinemia: from diagnosis to treatment,” Revista Brasileira de Anestesiologia, vol. 58, no. 6, pp. 651–664, 2008.

S. Curry, “Methemoglobinemia,” Annals of Emergency Medicine, vol. 11, no. 4, pp. 214–221, 1982.

J. W. Harvey and A. S. Keitt, “Studies of the efficacy and potential hazards of methylene blue therapy in aniline-induced methaemoglobinaemia,” British Journal of Haematology, vol. 54, no. 1, pp. 29–41, 1983.

Daily Med Current Medication Information, National Library of Medicine, Methylene Blue, 2010, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9ba51c5c-2bfe-44c7-92ab-87b54e4f89e6#nlm34090-1.

K. Buchholz, R. H. Schirmer, J. K. Eubel et al., “Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 1, pp. 183–191, 2008.

P. K. Gillman, “Methylene blue is a potent monoamine oxidase inhibitor,” Canadian Journal of Anaesthesia, vol. 55, no. 5, pp. 311–312, 2008.

P. K. Gillman, “Methylene blue implicated in potentially fatal serotonin toxicity,” Anesthesia, vol. 61, no. 10, pp. 1013–1014, 2006.

A. Z. Ables and R. Nagubilli, “Prevention, recognition, and management of serotonin syndrome,” American Family Physician, vol. 81, no. 9, pp. 1139–1142, 2010.

Medicines and Healthcare Products Regulatory Agency, Drug Safety Update, vol. 2, no. 9, 2009.

T. Jansen, S. Barnung, C. R. Mortensen, and E. C. Jansen, “Isobutyl-nitrite-induced methemoglobinemia; treatment with an exchange blood transfusion during hyperbaric oxygenation,” Acta Anaesthesiologica Scandinavica, vol. 47, no. 10, pp. 1300–1301, 2003.